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Abstract
Purpose We sought to estimate the prevalence of potentially
inappropriate prescriptions (PIP) and potential prescribing
omissions (PPOs) using a subset of the STOPP/START
criteria in a population based sample of Irish adults aged
≥65 years using data from The Irish LongituDinal Study on
Ageing (TILDA).
Methods A subset of 26 PIP indicators and 10 PPO indicators
from the STOPP/START criteria were applied to the TILDA
dataset. PIP/PPO prevalence according to individual STOPP/
START criteria and the overall prevalence of PIP/PPO were
estimated. The relationship between PIP and PPOs and
polypharmacy, age, gender and multimorbidity was examined
using logistic regression.
Results The overall prevalence of PIP in the study population
(n=3,454) was 14.6 %. The most common examples of PIP
identified were NSAID with moderate-severe hypertension
(200 participants; 5.8 %) and aspirin with no history of coro-
nary, cerebral, or peripheral vascular symptoms or occlusive
event (112 participants; 3.2 %). The overall prevalence of
PPOs was 30 % (n=1,035). The most frequent PPO was
antihypertensive therapy where systolic blood pressure con-
sistently >160mmHg (n=341, 9.9 %), There was a significant
association between PIP and PPO and polypharmacy when
adjusting for age, sex and multimorbidity (adjusted OR 2.62,
95 % CI 2.05–3.33 for PIP and adjusted OR 1.46, 95 % CI
1.23–1.75 for prescribing omissions).
Conclusion Our findings indicate prescribing omissions are
twice as prevalent as PIP in the elderly using a subset of the
STOPP/START criteria as an explicit process measure of
potentially inappropriate prescribing and prescribing omis-
sions. Polypharmacy was independently associated with both
PPO and PIP. Application of such screening tools to prescrib-
ing decisions may reduce unnecessary medication, related
adverse events, healthcare utilisation and cost.
Keywords Potentially inappropriate prescribing . Potential
prescribing omissions . STOPP . START . Older people
Introduction
Older adults are a heterogeneous group often presenting
with multimorbidity and polypharmacy. Prescribing in
older adults is challenging for a number of reasons as
any new medication must be considered in the context
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of the physiological effects of the drug, the absorption
and excretion of the drug and age-related changes in
body composition and physiology [1]. Potentially inap-
propriate prescribing (PIP) in older people refers to the
use of medications that should be generally avoided in
such populations and doses or frequencies of adminis-
tration that should not be exceeded [2, 3]. Medicines
that are considered potentially inappropriate lack evi-
dence based indications, are not cost-effective and may
pose a higher risk of adverse events including increases
in morbidity, adverse drug events, hospitalisation and
mortality [4, 5]. In terms of assessing the appropriate-
ness of prescribing in older people, both implicit and
explicit measures of process (providers’ actions) and
outcome (e.g., adverse drug events) are used [6]. Im-
plicit process measures involve a clinician’s judgment of
appropriateness for the individual patient based on pa-
tient characteristics and published work [7]. Explicit
process measures are criterion-based and are derived
from published evidence based reviews, expert opinion
and/or consensus [8, 9].
A comprehensive and explicit process measure of PIP
has been developed and validated for use in European
countries. The STOPP criteria (Screening Tool for Older
Persons’ Prescriptions) are a physiological system based
screening tool and comprises 65 clinically significant
criteria [10]. The criteria include commonly encountered
instances of PIP in older people such as drug–drug and
drug–disease interactions, drugs which adversely affect
older patients at risk of falls and duplicate drug class
prescriptions. In addition, under-prescribing of clinically
indicated medications has been identified by an accom-
panying screening tool known as the START criteria
(Screening Tool to Alert doctors to Right Treatment),
comprising 22 criteria for potentially appropriate drugs.
There have been few national studies of PIP and PPOs
in the general population of older people. In 2007, a subset
of the STOPP criteria was applied in a national population
study carried out in the Republic of Ireland among people
aged ≥70 years, using the Health Services Executive Pri-
mary Care Reimbursement Services (HSE-PCRS) pharmacy
claims database [6]. This study reported PIP prevalence
rates of 36 % in the primary care setting. However, this
study was limited in its assessment of PIP as the HSE-
PCRS database contains no information on diagnosis and
so only a subset of the STOPP criteria could be applied.
PIP prevalence rates reported may not have adequately
reflected all instances of PIP among older people such as
drug-disease interactions. Therefore, the overall aim of the
current study is to estimate the prevalence of PIP/PPOs,
particularly relating to drug-disease interactions, in a na-
tionally representative sample of individuals aged ≥65 years,
using a subset of the STOPP/START criteria.
Methods
Study population
The Irish LongituDinal Study on Ageing (TILDA) is a na-
tionally representative cohort study of people aged 50 years
and over and resident in Ireland, charting their health, social
and economic circumstances over a 10-year period. The first
wave of the TILDA study has been completed, and we have
examined the data from this cross sectional wave in our
current study. The STROBE standardised reporting guidelines
for cross-sectional studies have been followed to ensure the
uniform conduct and reporting of the research. All participants
aged ≥65 years are included [11].
Overview of TILDA data collection
Data for the current study was captured from three methods
used to collect data in the TILDA dataset. Participants first
completed a computer-assisted personal interview (CAPI) in
their own homes. Detailed information on all aspects of the
respondents’ lives was collected in the CAPI, including eco-
nomic status, health aspects (physical, mental, service needs
and usage) and social participation. Participants were then
invited to one of two health centres for a comprehensive health
assessment. Health assessments were carried out by qualified
and trained research nurses. Cognitive, cardiovascular, gait
and balance and vision measurements and tests were taken
in the health assessment. Finally, each participant was also
requested to complete and return a questionnaire designed to
explore certain areas that were considered particularly sensi-
tive for respondents to answer directly to an interviewer (e.g.,
relationship quality, depression and loneliness). The names of
medications that participants were taking at the time of the
CAPI, including over-the-counter medications, were coded in
the TILDA dataset using the World Health Organization
(WHO) Anatomical Therapeutic Chemical (ATC) classifica-
tion system. No information was collected on strength, quan-
tity, duration or cost of prescription.
Application of the STOPP/START criteria
Inappropriate drug-drug and drug-disease combinations ac-
cording to the STOPP criteria were identified using informa-
tion onmedications and diagnoses (e.g., hypertension, chronic
obstructive pulmonary disease, glaucoma) from the TILDA
dataset. In the absence of diagnosis information, prescription
drugs for the treatment of certain conditions were used as
proxies (e.g., gout, epilepsy). Medications documented by
the field-researchers at the CAPI interview were recorded in
the TILDA dataset using theWHOATC classification system.
A similar approach was used to identify PPOs. Twenty-six
STOPP criteria and ten START criteria were applied to the
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TILDA database. Table 1 contains details of the criteria ap-
plied per physiological system. Reasons for exclusion of
criteria are contained in Supplemental Table 1.
Statistical analysis
Data analyses were performed using Stata version 12
(StataCorp, College Station, Tx, USA) and statistical signifi-
cance at p<0.05was assumed. Descriptive statistics were used
to summarise the population. The overall prevalence of PIP/
PPO and the prevalence per individual STOPP/STARTcriteria
were calculated as a proportion of all eligible persons
≥65 years. The prevalence of STOPP/STARTcriteria was also
calculated as a proportion of the overall disease or drug
prevalence (e.g., beta-blocker with COPD as a proportion of
COPD prevalence or two concurrent opiates as a proportion of
opiate prevalence). Participants were further classified by
gender and age group (65–74 years, ≥75 years). Other explan-
atory variables examined included polypharmacy, defined as
concurrent use of five or more medications [12] and number
of chronic conditions (none versus 1, 2, 3 or more). Univariate
analyses confirmed that explanatory variables (polypharmacy,
age, gender and multimorbidity) were significantly associated
with PIP/PPOs. The association among any PIP/PPO (versus
none) and age, gender, polypharmacy and multimorbidity was
assessed using logistic regression and presented as adjusted
odds ratios with 95 % confidence intervals.
Results
Population descriptive statistics
A total of 3,507 people ≥65 years in Ireland were identified
from the TILDA database of which 1,842 (52.5 %) were
female and 1,665 (47.5 %) were male. Almost two thirds of
individuals were aged between 65 and 74 years (n=2,163).
The remaining 38 % (n=1,344) were aged ≥75 years. Fifty-
three participants reported missing medication data; theref,ore
the STOPP/STARTcriteria were applied to 3,454 participants.
Overall prevalence of PIP and PPOs
The overall prevalence of PIP was 14.6 % (n=504) consider-
ing all 26 STOPP criteria. Almost 13 % of the population (n=
433) were prescribed one potentially inappropriate medica-
tion, 60 (1.7 %) were prescribed two and 11 (0.3 %) were
prescribed three or more. The overall prevalence of PPOs was
30 % (n=1,035) considering the ten included START criteria.
Eight hundred and four individuals (23.3 %) presented with
one PPO, 188 (5.4 %) with two and 43 (1.2 %) with three or
more PPOs.
Prevalence of PIP according to individual STOPP criteria
Table 2 presents the prevalence of each of the individual
STOPP criteria by physiological system. Prescription of a
non-steroidal anti-inflammatory drug (NSAID) with
moderate-severe hypertension was the most frequent poten-
tially inappropriate drug (n=200, 5.8 %). The second most
frequent PIP was aspirin with no history of coronary, cerebral,
or peripheral vascular symptoms or occlusive event (n=112,
3.2 %), followed by benzodiazepines in those prone to falls
(n=40, 1.2 %) and aspirin with a past history of peptic ulcer
disease without a histamine H2 receptor antagonist or proton
pump inhibitor (n=38, 1.1 %). Angiotensin Converting En-
zyme (ACE) inhibitors (n=23, 0.7 %) and NSAIDs (n=21,
0.6 %) were the most frequently prescribed duplicate drugs
(Table 2).
Prevalence of PPOs according to individual START criteria
Table 3 presents the prevalence of each of the individual
START criteria by physiological system. The most frequent
PPO was antihypertensive therapy where systolic blood pres-
sure consistently >160 mmHg (n=341, 9.9 %), followed by
the omission of warfarin in the presence of chronic atrial
fibrillation (n=270, 7.8 %) and statin therapy in diabetes
mellitus if one or more co-existing major cardiovascular risk
factors were present (n=235, 6.8 %).
Table 1 STOPP/START criteria applied to the TILDA dataset
Physiological system Number of
criteria included
Percentage of
criteria included
STOPP criteria
Cardiovascular system 8/17 47.1 %
CNS & psychotropic drugs 4/13 30.8 %
Gastrointestinal system 1/5 20 %
Respiratory system 2/3 66.7 %
Musculoskeletal system 4/8 50 %
Urogenital system 2/6 33.3 %
Endocrine system 1/4 25 %
Drugs that adversely affect
those prone to falls
3/5 60 %
Analgesic drugs 0/3 0 %
Duplicate drug classes 1/1 100 %
START criteria
Cardiovascular system 5/8 62.5 %
Respiratory system 0/3 0 %
Central nervous system 2/2 100 %
Gastrointestinal system 0/2 0 %
Musculoskeletal system 0/3 0 %
Endocrine system ¾ 75 %
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Table 2 STOPP criteria applied to TILDA data for all those aged ≥65 years in Ireland in 2010
STOPP criteria description Potentially
inappropriate
prescription (n)
Potentially
inappropriate
prescription (%)
Proportionate
prescribing per
indication (%)a
Cardiovascular system
Loop diuretic as first line-monotherapy for hypertension
(safer, more effective alternatives available)
9 0.26 0.55
Thiazide diuretic with a history of gout (may exacerbate gout) 3 0.09 3.80
Beta-blocker with COPD (risk of increased bronchospasm) 31 0.90 18.02
Beta-blocker with verapamil (risk of symptomatic heart block) 4 0.12 0.52
Aspirin and warfarin without histamine H2 receptor antagonist
(except cimetidine) or proton pump inhibitor
(high risk of gastrointestinal bleeding)
13 0.38 1.00
Dipyridamole as monotherapy for cardiovascular secondary
prevention (no evidence of efficacy)
5 0.14 0.20
Aspirin with a past history of peptic ulcer disease without histamine
H2 receptor antagonist or Proton Pump Inhibitor (risk of bleeding)
38 1.10 16.38
Aspirin with no history of coronary, cerebral, or peripheral vascular
symptoms or occlusive event (not indicated)
112 3.24 12.50
Central nervous system and psychotropic drugs
TCA and glaucoma (exacerbate glaucoma) 3 0.09 2.36
TCA and opiate or calcium channel blockers (risk of severe constipation) 16 0.46 2.36
Phenothiazines in patients with epilepsy (may lower seizure threshold) 3 0.09 2.46
Anticholinergics to treat extra-pyramidal side-effects of neuroleptic
medications (risk of anticholinergic toxicity)
3 0.09 6.82
Gastrointestinal system
Prochlorperazine or metoclopramide with parkinsonism
(risk of exacerbating parkinsonism)
1 0.03 3.23
Respiratory system
Theophylline as monotherapy for COPD (safer, more effective
alternative: risk of adverse effects due to narrow therapeutic index)
11 0.32 6.40
Nebulised ipratropium with glaucoma (exacerbate glaucoma) 0 – –
Musculoskeletal system
NSAID with history of peptic ulcer disease or gastrointestinal
bleeding, unless with concurrent histamine H2 receptor antagonist,
PPI or misoprostol (risk of peptic ulcer relapse)
10 0.29 4.31
NSAID with moderate-severe hypertension (moderate:
160/100–179/109 mmHg; severe: ≥180/110 mmHg)
(risk of exacerbation of hypertension)
200 5.79 10.92
NSAID with heart failure (risk of exacerbation of heart failure) 5 0.14 9.26
Warfarin and NSAID (risk of gastrointestinal bleeding) 8 0.23 1.57
Urogenital system
Antimuscarinic drugs with chronic glaucoma (>3 months)
(risk of acute exacerbation of glaucoma)b
5 0.15 3.94
Alpha-blockers in males with frequent incontinence i.e., one or
more episodes of incontinence daily (risk of urinary frequency
and worsening of incontinence)c
9 0.55 8.18
Endocrine system
Glibenclamide or chlorpropamide with type 2 diabetes mellitus
(risk of prolonged hypoglycemia)
3 0.09 0.82
Drugs that adversely affect those prone to falls (≥ 1 fall in past 3 months)
Benzodiazepines (sedative, may cause reduced sensorium, impair balance)d 40 1.16 14.55
Neuroleptic drugs (may cause gait dyspraxia, Parkinsonism)d 6 0.17 2.18
First generation antihistamines (sedative, may impair sensorium)d 1 0.03 0.36
Duplicate drug class prescription (optimization of monotherapy within a single drug class)
Two concurrent opiates 3 0.09 2.26
Two concurrent NSAIDs 21 0.61 5.97
Two concurrent SSRIs 0 – –
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Factors associated with PIP
Any PIP was more likely in people ≥75 years than those 65–
74 years when adjusting for gender (OR 1.41, 95 % CI 1.16–
1.70). This association remained significant after additionally
adjusting for polypharmacy (age ≥75 years vs. 65–74 years,
OR 1.22, 95 % CI 1.00–1.50). There was no association
between PIP and gender when adjusting for age (F vs. M,
OR 1.05, 95 % CI 0.87–1.26). Supplemental Table 2 presents
the association between gender and age and PIP by individual
STOPP criteria. There was a strong association between any
PIP and polypharmacy when accounting for age and gender
(OR 3.13, 95 % CI 2.53–3.87), and this association remained
significant when additionally adjusting for the presence of
chronic conditions (OR 2.62, 95 % CI 2.05–3.33).
Factors associated with PPOs
There was no difference in the likelihood of a PPO in those
≥75 years when compared to those 65–74 years when
Table 2 (continued)
STOPP criteria description Potentially
inappropriate
prescription (n)
Potentially
inappropriate
prescription (%)
Proportionate
prescribing per
indication (%)a
Two concurrent antidepressants 2 0.06 3.03
Two concurrent loop diuretics 0 – –
Two concurrent ACE inhibitors 23 0.67 2.28
COPD chronic obstructive pulmonary disease, TCA tricyclic antidepressant, NSAID non-steroidal anti-inflammatory drug, SSRI selective serotonin
reuptake inhibitor, ACE inhibitors angiotensin converting enzyme inhibitors and Angiotensin receptor blockers
a Proportionate prescribing per indication, e.g., prevalence of STOPP criteria as a proportion of the overall disease or drug prevalence, e.g.,Beta-blocker
with COPD as a proportion of COPD prevalence, two concurrent opiates as a proportion of opiates prevalence
b 8 (0.23 %) missing data for chronic glaucoma variable
c Proportion of male participants only, 5 (0.30 %) missing data for urinary incontinence variable
d 1 (0.03 %) missing data for falls in past year variable
Table 3 START (Screening Tool to Alert doctors to Right Treatment) criteria applied to TILDA data for all those aged ≥65 years in Ireland in 2010
START criteria description Potential
prescribing
omissions (n)
Potential
prescribing
omissions (%)
Proportionate prescribing
omission per indication (%)*
Cardiovascular system
Warfarin in the presence of chronic atrial fibrillation 270 7.82 75.00
Antihypertensive therapy where systolic blood pressure consistently >160 mmHg † 341 9.87 18.62
Angiotensin Converting Enzyme (ACE) inhibitor with chronic heart failure 23 0.67 42.59
ACE inhibitor following acute myocardial infarction 126 3.65 47.19
Beta-blocker with chronic stable angina 151 4.37 45.21
Central nervous system
L-DOPA in idiopathic Parkinson’s disease with definite functional
impairment and resultant disability
3 0.09 17.65
Antidepressant drug in the presence of moderate-severe depressive
symptoms lasting at least 3 months §
44 1.30 70.97
Endocrine system
ACE inhibitor or Angiotensin Receptor Blocker in diabetes with
nephropathy, i.e., overt urinalysis proteinuria
13 0.38 44.83
Antiplatelet therapy in diabetes mellitus if one or more co-existing
major cardiovascular risk factor present (hypertension,
hypercholesterolaemia, smoking history)
110 3.18 35.48
Statin therapy in diabetes mellitus if one or more co-existing major
cardiovascular risk factor present
235 6.80 75.81
*Proportionate prescribing omission per indication, e.g. prevalence of PPO as a proportion of the overall disease, e.g. no warfarin with chronic atrial
fibrillation as a proportion of chronic atrial fibrillation prevalence
§ 70 (2.03 %) missing data for depressive symptoms variable
† 1,119 (32.40 %) missing data for blood pressure variable
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adjusting for gender (OR 1.09, 95 % CI 0.92–1.28). However,
omissions were significantly more likely in males when com-
pared to females when adjusting for age (OR 0.73, 95 % CI
0.63–0.85). The association between PPOs and gender
remained significant after also adjusting for polypharmacy
(OR 0.71, 95% CI 0.61–0.83). Supplemental Table 3 presents
the association between gender and age and PPOs by individ-
ual START criteria. There was a significant association be-
tween PPOs and polypharmacy when adjusting for age and
gender (OR 2.28, 95%CI 1.93–2.69) and this association also
remained significant when also adjusting for number of chron-
ic conditions (OR 1.46, 95 % CI 1.23–1.75).
Discussion
Statement of principal findings
This current study found that almost 15 % of people aged
≥65 years in the Republic of Ireland received at least one PIP,
according to a subset of 26 STOPP criteria. PIP was more
likely in older adults (≥75 years) when adjusting for gender
and polypharmacy. The overall prevalence of potential pre-
scribing omissions was 30 % considering the ten included
START criteria. Omissions were significantly more likely in
males when compared to females when adjusting for age and
polypharmacy. There was a significant association between
PIP/PPOs and polypharmacy when adjusting for age, gender
and multimorbidity.
Results in the context of current literature
This study presents a snapshot of the prevalence of PIP in a
nationally representative population of people aged ≥65 years
using data from the first wave of TILDA. Previous research is
limited by having focused on specific groups in particular clinical
settings as well as having measured PIP using Beers’ criteria
derived in the US [13–16]. A limited number of studies of PIP in
the general population of older people exist. In a previous Irish
study using data from the HSE-PCRS, an overall prevalence of
36 % in patients ≥70 years was reported using a subset of 30
STOPP criteria [6]. Similar results were reported in a study of the
Enhanced PrescribingDatabase (EPD) inNorthern Irelandwhere
the overall prevalence of PIP was 34 % [5]. However, the
differences between the TILDA database and these prescription
reimbursement databases make comparisons more difficult. The
lack of clinical information relating to diagnoses (e.g., hyperten-
sion, CVA) in the EPD and PRCS databases and the lack of
information on drug duration, dose or frequency of administra-
tion of prescriptions in the TILDA dataset mean that only a
limited number of the STOPP criteria applied in the three studies
are similar. In the EPD and PCRS databases, the most prevalent
PIP drugs were proton pump inhibitors (PPIs) at maximum
therapeutic dosage for >8 weeks, followed by NSAIDs for
>3 months and long-acting benzodiazepines for >1 month [5,
6]. These instances of PIP were not captured in TILDA. Simi-
larly, the use of a NSAID with moderate-severe hypertension
was the most prevalent PIP in TILDA, and this could not be
assessed in the prescription databases due to a lack of clinical
information. Of the 19 STOPP criteria that were the same in
PCRS and TILDA, the prevalence of PIPs are broadly similar,
but low in both datasets (<2.5 %).
The significant association between PIP and polypharmacy
is consistent with findings reported in previous studies [5, 6,
17], evenwhen age, gender andmultimorbidity is accounted for
[18]. While it is well recognised that the use of multiple
medications in the older adults is associated with increased risk
of adverse events such as adverse drug events in patients taking
NSAIDs (e.g., gastrointestinal haemorrhage) and increased in-
cidence of falls and cognitive impairment in those taking
sedative-hypnotic drugs, thesemedications are routinely among
the most common PIPs [3, 6, 19], as was the case in our study.
We also found an association between advancing age and PIP
after adjusting for polypharmacy, similar to a previous primary
care based study [20]. We reported no association between PIP
and gender after adjustments for age. These findings are con-
trary to previous studies reporting that women are more likely
to receive a PIP when compared with men [6, 17, 21].
Our overall findings relating to the prevalence of PPOs are
similar to previous studies that have used the START criteria
in a primary care setting [20]. Other studies have reported
higher prevalence rates of omissions among an older hospital
inpatient population [22, 23]. However, older patients admit-
ted to hospital are sicker and frailer than those in the commu-
nity so the findings need to be considered in the context of the
population of interest. The cardiovascular system accounted
for the majority of PPOs in keeping with previous reports [20].
Our study demonstrated that polypharmacy is associated with
the under-prescribing of indicated medicines even when
adjusting for age, gender and co-morbid conditions. Similar
findings have been reported in other studies, particularly those
with co-morbid conditions [24, 25]. However, these findings
warrant further investigation.
We also noted that over 70 % of study participants
who reported moderate-severe depressive symptoms were
not prescribed an antidepressant drug. Depressive symp-
toms were assessed in TILDA using the Center for Epi-
demiologic Studies Depression Scale (CES-D) [26]. We
used a cut off score of ≥27 points on the CES-D scale
as a proxy for diagnosis of ‘moderate-severe’ depressive
symptoms. This interpretation is the most conservative
estimate reported in the literature [27]; therefore, our find-
ings need to be considered in the context of these short-
comings. It may be that other management approaches
were adopted in the treatment of depressive symptoms
such as cognitive behavioural therapy [28].
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Clinical and policy implications
The term ‘potentially’ is used as there is often limited evidence
to support the inclusion of particular medications in lists of
drugs to avoid in particular populations. However, their use or
lack thereof may be indicated and appropriate in certain cir-
cumstances considering the clinical presentation of the patient
and the balance of the risk and benefits [5]. Clinical vigilance
and quality efforts should place particular focus onmedication
appropriateness, both with respect to under-prescribing and
over-prescribing. Reducing PIP in older people will require
implementation of more robust methods of medication re-
views to routinely assess drug effectiveness, dosage, duration,
interactions and adverse effects [29, 30].
The updated NICE guidelines (2013) on falls assessment
and prevention in older people highlight the importance of a
medication review in older people at risk of falls who present
to healthcare professionals. There is a lack of experimental
research on the use of the STOPP criteria as a tool to reduce
the incidence of adverse drug events (ADEs) such as falls in
older people. However, a recent randomised controlled trial
demonstrated that the application of the STOPP criteria sig-
nificantly improved medication appropriateness when com-
pared with the usual pharmaceutical care in 400 hospital
inpatients [3]. The study was not powered to detect a reduction
in secondary outcomes such as ADEs but further research is
warranted to examine the role of medicines reviews based on
the STOPP criteria as an intervention tool to attenuate ADE
incidence. In addition, reducing the number of drugs used by
older people may serve to reduce the risk of falls and the
associated direct and indirect costs [29].
Strengths and weaknesses of the study
The TILDA database contains data on morbidities (>99.5 %
complete) that enable the assessment of PIP in the context of a
given diagnosis (e.g., hypertension, cardiovascular condi-
tions). These data also facilitate the assessment and measure-
ment of errors of omission, i.e., the lack of use of appropriate
drugs when needed. However, it was only possible to apply a
subset of the STOPP/START criteria to the database, as de-
scribed in Table 1, due to a lack of information on drug
strength, dose and duration of prescriptions. This may have
led to an underestimate of the true prevalence of PIP/PPO
among older people in TILDA. In addition, the validity of the
original criteria is diminished by only applying a subset and
the comparability to other population based studies is limited
due to the differences in criteria applied.
The cost of PIP was not considered in the present study, but
a previous study estimated the cost of PIP to be in excess of
€45 million using a subset of 30 STOPP criteria [6]. Further
research is planned to link the TILDA dataset to the national
prescribing database (HSE-PCRS) to facilitate the application
of 19 additional STOPP criteria and to estimate the cost of PIP
using these linked datasets. In addition, there is a need to
compare these findings with other European population based
studies. The association between explicit process measures of
PIP and prescribing omissions, and health outcomes (morbid-
ity and mortality) and healthcare utilisation also requires fur-
ther investigation to facilitate the development and testing of
appropriate interventions to reduce PIP and PPOs in older
adults. In the Irish context, this can be completed using future
waves of the TILDA data.
Conclusion
Our findings indicate PIP and PPOs are prevalent in the
elderly using a subset of the STOPP/START criteria as an
explicit process measure of potentially inappropriate prescrib-
ing and PPOs. Application of such screening tools to prescrib-
ing decisions may reduce unnecessary medication, related
adverse events, healthcare utilisation and cost.
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